We use cookies for a better user experience. Read our Privacy Policy

I Agree

Chronic Focal Encephalitis Market

Chronic Focal Encephalitis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Chronic Focal Encephalitis Market: Introduction

  • Chronic focal encephalitis (CFE) is an uncommon but deadly inflammatory brain illness in which individuals fight their own immune system. Chronic focal encephalitis is also known as Rasmussen's encephalitis which causes inflammation of brain and can result in the destruction or removal of a portion of the brain in children.
  • A team of researchers from the Université de Montréal, the CHU Sainte-Justine, and the Université de Montréal Hospital (CHUM) research centers recently confirmed what scientists had suspected through experiments on humanized mice: the disease is autoimmune, meaning it attacks patients using their own immune system.
  • Typically, people with CFE experience focal seizures that can evolve to epilepsia partialis continua (near continuous seizures) (EPC). EPC is defined by a rapid, rhythmic succession of contractions and relaxations of a muscle or muscle group (myoclonus), typically of the arms, legs, and face, which can occur singly or in a continuous, repeated series. This happens on one side of the body, opposite to the side of the inflammation in Rasmussen.

Key Drivers, Restraints, and Opportunities of Global Chronic Focal Encephalitis Market

  • The worldwide chronic focal encephalitis treatment market is expected to be driven by an increase in the number of instances of chronic focal encephalitis. CFE is a kind of persistent brain inflammation that worsens with time. The inflammation usually affects one hemisphere of the brain, or cerebral hemisphere, and results in severe epileptic activity, such as persistent, focal seizures. People with CFE may have irreversible brain damage, loss of motor skills, and mental decline as a result of the persistent inflammation of the brain. The illness is extremely rare, with about 200-500 instances reported globally, and it usually affects children aged 2 to 10.
  • CFE therapy aims to reduce inflammation during the acute period. Steroids, similar to that with other inflammatory illnesses, may be administered first, either as a high-dosage therapy for a short period of time or as a lower dose for long-term treatment. Intravenous immunoglobulin is also beneficial in the short- and long-term, especially in adults, where it is recommended as a first-line therapy. Plasmapheresis and tacrolimus are two more comparable therapies; albeit there is less proof for them. None of these therapies can avoid the onset of lifelong impairment.
  • Treatment is focused at alleviating the remaining symptoms during the residual stage of the illness, when there is no active inflammation. Standard anti-epileptic medications are typically unsuccessful in managing seizures; therefore, a hemispherectomy or a corpus callosotomy may be required to surgically remove or detach the afflicted cerebral hemisphere. This generally leads to further weakening, hemianopsia, and cognitive issues, but in rare cases, especially in young children, the opposite side of the brain may be able to take up some of the work. If the left hemisphere is damaged, the surgery may not be recommended since this hemisphere includes the majority of the regions of the brain that regulate language. Hemispherectomy, on the other hand, is frequently extremely helpful in decreasing seizures.
  • Less awareness about the symptoms and signs of chronic focal encephalitis hamper the global chronic focal encephalitis market. Moreover, there is limited proven efficiency for treatment of chronic focal encephalitis. This is likely to restrain the global market.

North America to Capture Major Share of Global Chronic Focal Encephalitis Market

  • North America is projected to account for major share of the global chronic focal encephalitis market due to an increase in technological advancements, preference for surgical therapy for CFE, and rise in prevalence of chronic focal encephalitis.
  • Europe is expected to account for the second-largest share of the global chronic focal encephalitis market during the forecast period. The market in the region is likely to expand at a significant CAGR from 2021 to 2031.

Key Players Operating in Global Chronic Focal Encephalitis Market

The global chronic focal encephalitis market is highly fragmented, with the presence of various key players. A large number of manufacturers hold a major share in their respective regions. Major players operating in the global chronic focal encephalitis market are:

  • Abbott
  • Cephalon
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Sanofi
  • Sunovion Pharmaceuticals

Global Chronic Focal Encephalitis Market: Research Scope

Global Chronic Focal Encephalitis Market, by Treatment

  • Medication
  • Surgery

Global Chronic Focal Encephalitis Market, by End-user

  • Hospitals
  • Specialty Clinics
  • Others

Global Chronic Focal Encephalitis Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa
Chronic Focal Encephalitis Market

Interested in this report?
Get a FREE Brochure now!

Request Brochure

*Get Brochure (PDF) sent to your email within minutes

N/A

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

369

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved